Pengaruh tenofovir terhadap kejadian mikroalbuminuria pada orang dengan HIV AIDS (ODHA) yang mendapat terapi antiretroviral (ARV)
DAFTAR PUSTAKA
1. Fauci AS, Lane HC. “Human Immunodeficiency Virus disease: AIDS
and related disorders.” Dalam: Harrison’s Principles of Internal
Medicine. Eds.Kasper DL, Braunwald E, Fauci AS, Longo DL, Hauser
SL, et al. 16th ed. Vol.1. New York. Mc Graw Hill Companies. 2008.
1076-98.
2. Djoerban Z, Djauzi S. “HIV/AIDS di Indonesia.” Dalam: Buku Ajar
Ilmu Penyakit Dalam. Eds.Setiati S, Alwi I, Sudoyo AW, Simadibrata
M, Setiyohadi B,et al. Edisi VI. Jilid 1. Jakarta. Interna Publishing. Juli
2014. 887-97.
3. Kementerian
Kesehatan
Republik
Indonesia.
Peraturan
Menteri
Kesehatan Republik Indonesia Nomor 87 Tahun 2014. Tentang
Pedoman Pengobatan Antiretroviral. Kemenkes RI. 2014.
4. United Nations Programme on HIV/AIDS. Global report: UNAIDS
report on the Global AIDS epidemic 2012. UNAIDS. 2012
5. Direktorat Jendral PP & PL. Statistik Kasus HIV/AIDS di Indonesia
dilapor s/d September 2014. Dirjen PP&PL Kemenkes RI. 2014
6. Levy J.A. HIV Pathogenesis: 25 years of progress and persistent
challenges. AIDS, 23, 2009, 147-60
7. World Health Organization. Antiretroviral therapy for HIV infection in
adults and adolescents: Recommendations for a public health approach.
WHO. 2010
8. Kementerian Kesehatan Republik Indonesia. Pedoman Nasional
Tatalaksana Klinis Infeksi HIV dan Terapi Antiretroviral pada Orang
Dewasa dan Remaja. Direktorat Jenderal Pengendalian Penyakit dan
Penyehatan Lingkungan Kemenkes RI. 2011
9. Fernandez BF, Ferrer AM, Sanz AB, Nino MDS, Izquierdo MC, et al.
Tenofovir nephrotoxicity: 2011 Update. AIDS research and treatment.
2011. 1-12
38
Universitas Sumatera Utara
10. Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D’Agati VD,et al.
Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical,
pathological, and mitochondrial abnormalities. International Society of
Nephrol. 2010. Vol 78. 1171-1177.
11. Kalyesubula R, Perazella MA. Nephrotoxicity of HAART. AIDS
research and treatment. 2011. 1-12
12. Scherzer R, Estrella M, Li Y, Deeks SG, Grunfeld C, et al. Association
of tenofovir exposure with kidney disease risk in HIV infection. AIDS.
April 2012. Vol 26. 867-875.
13. Jafari A, Khalili H, Khavidaki SM. Tenofovir-induced nephrotoxicity:
incidence, mechanism, risk factors, prognosis and proposed agents for
prevention. Eur Jour Pharmacol. 2014. Vol 28. 1-12.
14. Chavez HL, Batista MP, Gomes AM, Costa AA, Lima AT, et al.
Microalbuminuria and kidney disease risk in HIV patients taking
combined antiretroviral therapy. World journal of AIDS. 2014. Vol 4.
242-248.
15. Kim PS, Woods C, Dutcher L, Georgoff P, Rosenberg A, et al. Increased
Prevalence of Albuminuria in HIV-Infected Adults with Diabetes. Plos
One Journal. 2011. Vol 6. 1-7.
16. Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, et al. Association
between Antiretroviral Exposure and Renal Impairment among HIVPositive Persons with Normal Baseline Renal Function: The D:A:D
Study. Journal of Infectious Diseases. 2013. Vol 207. 1359-1369.
17. Hadigan C, Edwards E, Rosenberg A, Purdy JB, Fleischman E, et al.
Microalbuminuria in HIV disease. Am J Nephrol. 2013. Vol 37. 443451.
18. Kelly MD, Gibson M, Bartlett H, Patten J, Rowling D. Tenofovir
associated proteinuria. JAIDS. 2013. Vol 23. 479-481.
19. Montagnier L. 25 Years after HIV discovery: Prospects for cure and
vaccine. Dalam: Nobel Lecture. World Foundation for AIDS Research
and Prevention. UNESCO. 2008
39
Universitas Sumatera Utara
20. US Government Source for HIV/AIDS. Medical Practice Guidelines,
Clinical Trials and Other Research Information. Dalam: The 7th
Glossary of HIV/AIDS-related terms. US Government. 2011
21. World Health Organization. Who Case Definitions of HIV and Revised
Clinical Staging and Immunological Clasification of HIV-related disease
in Adult and Children. WHO. 2007
22. Nasronudin. “Pendekatan Biologi Molekuler, Klinis dan Sosial.” Dalam:
HIV & AIDS. Ed. Nasronudin. Surabaya. Airlangga University Press.
2007
23. A Service of the U.S Departement of Health and Human Services. “The
HIV Life Cycle”. Dalam: AIDS Info. U.S Departement of Health and
Human Services. 2005.
24. Direktorat Jenderal Pemberantasan Penyakit Menular dan Penyehatan
Lingkungan Departemen Kesehatan RI. Pedoman nasional perawatan,
dukungan dan pengobatan bagi ODHA. Jakarta. Dep Kes RI. 2003
25. Wormser GP. AIDS and Other Manifestations of HIV. Ed. Wormser GP.
4th Ed. Academic Press. 2004.
26. Johnson D. Diagnosis,Classification and Staging of Chronic Kidney
Disease. Australia. Kidney Health. 2012. 1-31.
27. Bawazier LA. “Proteinuria.” Dalam: Buku Ajar Ilmu Penyakit Dalam.
Eds, Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B,et al.
Edisi VI. Jilid 2. Jakarta. Internal Publishing. 2014. 2306-2313.
28. Olah AV, Fodor B, Matyus J. Current question on proteinuria and
albuminuria. Jour Of Clin Metab & Diab. 2012. Vol 3. 1-8.
29. De Jong PE, Curhan GC. Screening,Monitoring and Treatment of
Albuminuria: Public Health Perspectives. J Am Soc Nephrol. 2006. Vol
17. 2120-2126.
30. Decloedt E, Maartens G. Drug induced renal injury. CME. 2011. Vol 29.
1-4.
31. Patel KK, Patel AK, Ranjan RR, Patel AR, Patel JK. Tenofovir
associated renal dysfunction in clinical practice: an observational cohort
40
Universitas Sumatera Utara
from western India. India. Journal Sex Transm Dis & AIDS. 2010. Vol
31. 30-34.
32. Sekretariat Jenderal Kementerian Kesehatan Republik Indonesia. Profil
Kesehatan Indonesia 2015. Kementerian Kesehatan RI. 2016.
33. Tongma C, Shikuma MC, Nakamoto BK. Albuminuria as a Marker of
Cardiovascular Risk in HIV Infected Individuals Receiving Stable
Antiretroviral Therapy. Hawai’i Journal of Medicine and Public Health.
September 2013. Vol 72 (9). 34-38
34. Van der Sande Mariane AB, Van der Loeff Marteen F, Aveika Akum A,
Sabally S. Body Mass Index at Time of HIV Diagnosis A Strong and
Independent Predictor of Survival. J Acquir Immune Defic Syndr. Oct
2004. Vol 37. 1288–1294.
35. A Koroshi. Microalbuminuria, is it so important?. Hippokratia. 2007.
Vol 11 (3). 105-107.
36. Purswani M, Kunjal P K, Kopp J B. Tenofovir Treatment Duration
Predicts Proteinuria in A Multiethnic United States Cohort of Children
and Adolescents With Perinatal HIV-1 Infection. The Pediatric
Infectious Disease Journal. 2013. Vol 32 (5). 495–500.
37. Bickel M, P Khaykin, C Stephan. Acute kidney injury caused by
tenofovir disoproxil fumarate and diclofenac co-administration. J HIV
Medicine. 2013. Vol 14. 633–638.
38. Ivanovna R, Efrida, Kurniati R. Analisis Kadar Kreatinin Serum
Sebelum dan Setelah Terapi Tenovofir pada Penyandang HIV di RS Dr.
M. Djamil Padang Periode 2012-2013. Jurnal Kesehatan Andalas. 2014.
Vol 3. 212-216.
41
Universitas Sumatera Utara
1. Fauci AS, Lane HC. “Human Immunodeficiency Virus disease: AIDS
and related disorders.” Dalam: Harrison’s Principles of Internal
Medicine. Eds.Kasper DL, Braunwald E, Fauci AS, Longo DL, Hauser
SL, et al. 16th ed. Vol.1. New York. Mc Graw Hill Companies. 2008.
1076-98.
2. Djoerban Z, Djauzi S. “HIV/AIDS di Indonesia.” Dalam: Buku Ajar
Ilmu Penyakit Dalam. Eds.Setiati S, Alwi I, Sudoyo AW, Simadibrata
M, Setiyohadi B,et al. Edisi VI. Jilid 1. Jakarta. Interna Publishing. Juli
2014. 887-97.
3. Kementerian
Kesehatan
Republik
Indonesia.
Peraturan
Menteri
Kesehatan Republik Indonesia Nomor 87 Tahun 2014. Tentang
Pedoman Pengobatan Antiretroviral. Kemenkes RI. 2014.
4. United Nations Programme on HIV/AIDS. Global report: UNAIDS
report on the Global AIDS epidemic 2012. UNAIDS. 2012
5. Direktorat Jendral PP & PL. Statistik Kasus HIV/AIDS di Indonesia
dilapor s/d September 2014. Dirjen PP&PL Kemenkes RI. 2014
6. Levy J.A. HIV Pathogenesis: 25 years of progress and persistent
challenges. AIDS, 23, 2009, 147-60
7. World Health Organization. Antiretroviral therapy for HIV infection in
adults and adolescents: Recommendations for a public health approach.
WHO. 2010
8. Kementerian Kesehatan Republik Indonesia. Pedoman Nasional
Tatalaksana Klinis Infeksi HIV dan Terapi Antiretroviral pada Orang
Dewasa dan Remaja. Direktorat Jenderal Pengendalian Penyakit dan
Penyehatan Lingkungan Kemenkes RI. 2011
9. Fernandez BF, Ferrer AM, Sanz AB, Nino MDS, Izquierdo MC, et al.
Tenofovir nephrotoxicity: 2011 Update. AIDS research and treatment.
2011. 1-12
38
Universitas Sumatera Utara
10. Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D’Agati VD,et al.
Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical,
pathological, and mitochondrial abnormalities. International Society of
Nephrol. 2010. Vol 78. 1171-1177.
11. Kalyesubula R, Perazella MA. Nephrotoxicity of HAART. AIDS
research and treatment. 2011. 1-12
12. Scherzer R, Estrella M, Li Y, Deeks SG, Grunfeld C, et al. Association
of tenofovir exposure with kidney disease risk in HIV infection. AIDS.
April 2012. Vol 26. 867-875.
13. Jafari A, Khalili H, Khavidaki SM. Tenofovir-induced nephrotoxicity:
incidence, mechanism, risk factors, prognosis and proposed agents for
prevention. Eur Jour Pharmacol. 2014. Vol 28. 1-12.
14. Chavez HL, Batista MP, Gomes AM, Costa AA, Lima AT, et al.
Microalbuminuria and kidney disease risk in HIV patients taking
combined antiretroviral therapy. World journal of AIDS. 2014. Vol 4.
242-248.
15. Kim PS, Woods C, Dutcher L, Georgoff P, Rosenberg A, et al. Increased
Prevalence of Albuminuria in HIV-Infected Adults with Diabetes. Plos
One Journal. 2011. Vol 6. 1-7.
16. Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, et al. Association
between Antiretroviral Exposure and Renal Impairment among HIVPositive Persons with Normal Baseline Renal Function: The D:A:D
Study. Journal of Infectious Diseases. 2013. Vol 207. 1359-1369.
17. Hadigan C, Edwards E, Rosenberg A, Purdy JB, Fleischman E, et al.
Microalbuminuria in HIV disease. Am J Nephrol. 2013. Vol 37. 443451.
18. Kelly MD, Gibson M, Bartlett H, Patten J, Rowling D. Tenofovir
associated proteinuria. JAIDS. 2013. Vol 23. 479-481.
19. Montagnier L. 25 Years after HIV discovery: Prospects for cure and
vaccine. Dalam: Nobel Lecture. World Foundation for AIDS Research
and Prevention. UNESCO. 2008
39
Universitas Sumatera Utara
20. US Government Source for HIV/AIDS. Medical Practice Guidelines,
Clinical Trials and Other Research Information. Dalam: The 7th
Glossary of HIV/AIDS-related terms. US Government. 2011
21. World Health Organization. Who Case Definitions of HIV and Revised
Clinical Staging and Immunological Clasification of HIV-related disease
in Adult and Children. WHO. 2007
22. Nasronudin. “Pendekatan Biologi Molekuler, Klinis dan Sosial.” Dalam:
HIV & AIDS. Ed. Nasronudin. Surabaya. Airlangga University Press.
2007
23. A Service of the U.S Departement of Health and Human Services. “The
HIV Life Cycle”. Dalam: AIDS Info. U.S Departement of Health and
Human Services. 2005.
24. Direktorat Jenderal Pemberantasan Penyakit Menular dan Penyehatan
Lingkungan Departemen Kesehatan RI. Pedoman nasional perawatan,
dukungan dan pengobatan bagi ODHA. Jakarta. Dep Kes RI. 2003
25. Wormser GP. AIDS and Other Manifestations of HIV. Ed. Wormser GP.
4th Ed. Academic Press. 2004.
26. Johnson D. Diagnosis,Classification and Staging of Chronic Kidney
Disease. Australia. Kidney Health. 2012. 1-31.
27. Bawazier LA. “Proteinuria.” Dalam: Buku Ajar Ilmu Penyakit Dalam.
Eds, Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B,et al.
Edisi VI. Jilid 2. Jakarta. Internal Publishing. 2014. 2306-2313.
28. Olah AV, Fodor B, Matyus J. Current question on proteinuria and
albuminuria. Jour Of Clin Metab & Diab. 2012. Vol 3. 1-8.
29. De Jong PE, Curhan GC. Screening,Monitoring and Treatment of
Albuminuria: Public Health Perspectives. J Am Soc Nephrol. 2006. Vol
17. 2120-2126.
30. Decloedt E, Maartens G. Drug induced renal injury. CME. 2011. Vol 29.
1-4.
31. Patel KK, Patel AK, Ranjan RR, Patel AR, Patel JK. Tenofovir
associated renal dysfunction in clinical practice: an observational cohort
40
Universitas Sumatera Utara
from western India. India. Journal Sex Transm Dis & AIDS. 2010. Vol
31. 30-34.
32. Sekretariat Jenderal Kementerian Kesehatan Republik Indonesia. Profil
Kesehatan Indonesia 2015. Kementerian Kesehatan RI. 2016.
33. Tongma C, Shikuma MC, Nakamoto BK. Albuminuria as a Marker of
Cardiovascular Risk in HIV Infected Individuals Receiving Stable
Antiretroviral Therapy. Hawai’i Journal of Medicine and Public Health.
September 2013. Vol 72 (9). 34-38
34. Van der Sande Mariane AB, Van der Loeff Marteen F, Aveika Akum A,
Sabally S. Body Mass Index at Time of HIV Diagnosis A Strong and
Independent Predictor of Survival. J Acquir Immune Defic Syndr. Oct
2004. Vol 37. 1288–1294.
35. A Koroshi. Microalbuminuria, is it so important?. Hippokratia. 2007.
Vol 11 (3). 105-107.
36. Purswani M, Kunjal P K, Kopp J B. Tenofovir Treatment Duration
Predicts Proteinuria in A Multiethnic United States Cohort of Children
and Adolescents With Perinatal HIV-1 Infection. The Pediatric
Infectious Disease Journal. 2013. Vol 32 (5). 495–500.
37. Bickel M, P Khaykin, C Stephan. Acute kidney injury caused by
tenofovir disoproxil fumarate and diclofenac co-administration. J HIV
Medicine. 2013. Vol 14. 633–638.
38. Ivanovna R, Efrida, Kurniati R. Analisis Kadar Kreatinin Serum
Sebelum dan Setelah Terapi Tenovofir pada Penyandang HIV di RS Dr.
M. Djamil Padang Periode 2012-2013. Jurnal Kesehatan Andalas. 2014.
Vol 3. 212-216.
41
Universitas Sumatera Utara